TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07426419: An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM)

Sponsor: Affinia Therapeutics · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 22 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$761,940

Rescue Site Savings

+$507,960

Unlock Full NCT07426419 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07426419 Rescue Dossier →